| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.12. | Celularity Inc - 8-K, Current Report | - | SEC Filings | ||
| 14.11. | Celularity Inc - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11. | Celularity Inc - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 28.10. | Celularity Inc - 8-K, Current Report | 2 | SEC Filings | ||
| CELULARITY Aktie jetzt für 0€ handeln | |||||
| 14.10. | Celularity's diabetic foot ulcer therapy shows promise in clinical trial | 1 | Investing.com | ||
| 14.10. | Celularity Inc.: Celularity Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Results Demonstrating the Safety and Efficacy of Human Placenta-Derived Cells (PDA-002) for Diabetic Foot Ulcers Complicated by Peripheral ... | 112 | GlobeNewswire (Europe) | First-in-class regenerative therapy for diabetic foot ulcers complicated by peripheral artery diseaseCelularity PDA-002 achieved durable wound healing with just two intramuscular dosesAs a qualified... ► Artikel lesen | |
| 09.09. | Celularity stock rating upgraded to Buy by WBB Securities on CMS reimbursement changes | 1 | Investing.com | ||
| 09.09. | WBB Securities stuft Celularity-Aktie nach Medicare-Reform auf 'Kaufen' hoch | 1 | Investing.com Deutsch | ||
| 29.08. | Celularity Inc - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 22.08. | Celularity receives Nasdaq notice regarding Form 10-Q | 1 | Seeking Alpha | ||
| 22.08. | Celularity, Inc.: Celularity Receives Nasdaq Notice Regarding Form 10-Q | 348 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company focused on addressing age-related... ► Artikel lesen | |
| 18.08. | Celularity tilgt im Zuge einer Restrukturierung sämtliche erstrangig besicherten Schulden | 1 | Investing.com Deutsch | ||
| 18.08. | Celularity retires all senior secured debt in restructuring deal | 3 | Investing.com | ||
| 12.08. | Celularity Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 30.07. | Celularity Inc - 8-K, Current Report | 1 | SEC Filings | ||
| 22.07. | Celularity Inc - 8-K, Current Report | 2 | SEC Filings | ||
| 15.07. | Celularity Inc. Surges Over 8% Pre-Market Amid Florida Stem Cell Policy, New Partnership Boost | 4 | Benzinga.com | ||
| 09.07. | Celularity, Inc.: Celularity & Fountain Life Announce Partnership to Deliver Stem Cell Therapies Under New Florida Law | 2 | GlobeNewswire (USA) | ||
| 01.07. | Celularity, Inc.: Celularity Hails New Florida Law Opening Patient Access to Stem Cell Therapies | 1 | GlobeNewswire (USA) | ||
| 10.06. | Celularity, Inc.: Celularity Announces Chief Financial Officer Transition | 156 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., June 10, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) ("Celularity" or the "Company"), a regenerative and cellular medicine company, today announced that it terminated... ► Artikel lesen |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 80,30 | +0,63 % | Rheinmetall Aktie: Sehr spannend! - BioNTech, Evotec, Klöckner, PNE und Stabilus im Marktbericht Börse Frankfurt | Wo ist am Aktienmarkt etwas los, welche Themen interessieren Anleger derzeit besonders? Vor allem für Trader ist es wichtig zu wissen, wo "die Musik spielt" und welche Themen an der Börse aktuell besonders... ► Artikel lesen | |
| EVOTEC | 5,190 | 0,00 % | Eilmeldung am Abend: EVOTEC SE rutscht brutal ab! | ||
| QIAGEN | 38,335 | 0,00 % | JEFFERIES stuft QIAGEN NV auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Qiagen mit einem Kursziel von 57 US-Dollar auf "Buy" belassen. Die Profitabilität dürfte 2026 zumindest stabil bleiben... ► Artikel lesen | |
| CUREVAC | 4,182 | -2,24 % | EILMELDUNG: Curevac-Aktie verliert deutlich - bricht jetzt das Vertrauen weg? | ||
| VALNEVA | 3,704 | -0,27 % | Valneva Reports Positive Final Phase 2 Antibody Persistence and Safety Results in Children for its Chikungunya Vaccine IXCHIQ | IXCHIQ- was well tolerated by children aged one to eleven years regardless of the dose or previous chikungunya infection (CHIKV) Antibody levels remained high after twelve months in both dose groups... ► Artikel lesen | |
| NOVAVAX | 5,608 | +0,07 % | Why I Wouldn't Touch Novavax With a 10-Foot Pole | ||
| STRYKER | 299,40 | 0,00 % | Medizintechnik-Anbieter Stryker hebt erneut Dividende an | ||
| CRISPR THERAPEUTICS | 48,000 | +0,42 % | CRISPR Therapeutics AG: CRISPR Therapeutics Announces Positive Phase 1 Clinical Data for CTX310 Demonstrating Deep and Durable ANGPTL3 Editing, Triglyceride and Lipid Lowering | -Data presented in a late-breaking presentation at the American Heart Association (AHA) Scientific Sessions 2025- -Phase 1 clinical data for CTX310® demonstrate robust, dose-dependent reductions in... ► Artikel lesen | |
| AAP IMPLANTATE | 1,320 | -4,35 % | aap Implantate: Kapitalerhöhung per Privatplatzierung | Die aap Implantate AG hat eine Barkapitalerhöhung um 788.150 Euro beschlossen, wodurch sich das Grundkapital auf 14,7 Millionen Euro erhöht. Die Maßnahme erfolgt durch die Ausgabe von 788.150 neuen... ► Artikel lesen | |
| BIOXXMED | 0,022 | 0,00 % | HV-Termine: Hauptversammlungen bei bioXXmed, Borussia Dortmund, CureVac, elexxion, Nanofocus, NSI Asset, OTRS | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Labs Appoints Tony Lialin as Chief Commercial Officer | SAN DIEGO, Aug. 14, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company" or "VivoSim Labs"), a pharmaceutical and biotechnology services company that is focused on providing testing... ► Artikel lesen | |
| MAINZ BIOMED | 1,030 | 0,00 % | Mainz BioMed NV: DoctorBox Adds Mainz Biomed's ColoAlert(R) to Its Portfolio | BERKELEY, Calif. and MAINZ, Germany, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) ("Mainz Biomed" or the "Company"), molecular genetics diagnostic company specializing in the... ► Artikel lesen | |
| INFLARX | 0,864 | +0,94 % | InflaRx N.V.: InflaRx Announces International Nonproprietary Name of "Izicopan" for INF904 | JENA, Germany, Dec. 11, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced... ► Artikel lesen | |
| SCORPIUS | 0,072 | 0,00 % | Tivic Acquires Scorpius Manufacturing Assets And Secures More Than $90 Million Financing | ||
| IBIO | 1,640 | +4,46 % | iBio, Inc.: iBio Reports Q1 Fiscal Year 2026 Financial Results and Provides Corporate Update | Strengthened cash position and extended runway into the fourth quarter of fiscal year 2027 after closing underwritten public offering with up to potentially $100 million of total gross proceeds Presented... ► Artikel lesen |